Hi There,
Let me assure I was in no way trying to minimising the benefit of SOZO for Lymphedema patients.
What I personally believe is that the market is more attuned to Renal and Heart products than lymphedema. I was not addressing what the company says about addressable markets but about pure perception of the common trader.
Most people know about Renal and Heart disease and treatments. Unfortunately and I do think it is unfortunate Lymphedema its causes, side effects and treatments not as widely known.
I'm a big believer in the company and all of the product here covering all treatments. Any progression in share price is good in my opinion and what the catalyst is I dont really mind
Keep Smiling Puk
Ann: FDA Grants Breakthrough Device Designation for Renal Failure, page-17
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.001(1.79%) |
Mkt cap ! $111.2M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 5.8¢ | 5.5¢ | $47.99K | 858.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 513413 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 102335 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IPD (ASX) Chart |